Last reviewed · How we verify
Apixiban
Apixiban is a Small molecule drug developed by Regeneron Pharmaceuticals. It is currently in Phase 2 development. Also known as: Eliquis.
Apixaban is an anticoagulant used to treat conditions such as ischemia, deep vein thrombosis, pulmonary embolism, and thrombosis, as well as thrombocytopenia. It is also being studied in combination with other treatments, including the LAmbre PlusTM Left Atrial Appendage Closure System, and compared to other therapies such as clopidogrel and aspirin.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Regeneron Pharmaceuticals is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Apixiban |
|---|---|
| Also known as | Eliquis |
| Sponsor | Regeneron Pharmaceuticals |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF (NA)
- A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants (PHASE2)
- Apixaban in Thrombocytopenia (EARLY_PHASE1)
- DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation (PHASE4)
- Clopidogrel Aspirin Therapy (CAT) Versus Apixiban Aspirin Therapy (AAT) After Lower Limb Revascularization (PHASE1, PHASE2)
- The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apixiban CI brief — competitive landscape report
- Apixiban updates RSS · CI watch RSS
- Regeneron Pharmaceuticals portfolio CI
Frequently asked questions about Apixiban
What is Apixiban?
Who makes Apixiban?
Is Apixiban also known as anything else?
What development phase is Apixiban in?
Related
- Manufacturer: Regeneron Pharmaceuticals — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Eliquis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing